<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="utf-8">
    <meta http-equiv="X-UA-Compatible" content="IE=edge">
    <meta content="width=device-width, initial-scale=1, maximum-scale=1, user-scalable=no" name="viewport">
    <meta name="description" content="نظام معلومات الأدوية السعودي Saudi Drugs Information System">
    <meta name="author" content="Saudi Food & Drug Authority (SFDA)">
    <noscript><meta http-equiv="refresh" content="0; url=/noScript.html" /></noscript>
    <link rel="shortcut icon" href="/favicon.ico">
    <title>&#x646;&#x638;&#x627;&#x645; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</title>
    <link href="/fonts/roboto/roboto.css?v=53F8z0aw8DRnG9ou9x1tuKMPbNjRZWM-VBHl3B0s9-o" rel="stylesheet" />
    <link href="/fonts/material-icons/materialicons.css?v=8pEJ8MWsFzHRDLY0NI5rssf6T6vankxrJDPnnZxOGrg" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-rtl.css?v=0env-Atj9mTPLILmJGwuDlLIOS_Akxxy4gnH1UUtrjU" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-glyphicons.css?v=U5a39oen_WYzVAAexH5aoahbpqlKHcIzQrnXujf1yio" rel="stylesheet" />
    <link href="/lib/bootstrap-select/dist/css/bootstrap-select.css?v=DeY2lH0e0tmNnO9XZ-gGVOGk6_YoWlZ49y7CnD3ST00" rel="stylesheet" />
    <link href="/lib/toastr/toastr.css?v=kKePN_CyxTiMEgsSDu_7z21ru07YOZtR-0UV0JOkt5o" rel="stylesheet" />
    <link href="/lib/famfamfam-flags/dist/sprite/famfamfam-flags.css?v=JVJiF3s2_kk99xQHfYhfxo_-Dd52ZIruDMOILwPkqv0" rel="stylesheet" />
    <link href="/lib/font-awesome/css/font-awesome.css?v=YIHlqxkiJtENTMuzIHC9EfZaB5RniGr7kF7juUQJUuc" rel="stylesheet" />
    <link href="/lib/Waves/dist/waves.css?v=nd3hxjNg6DhkuFIz5IbxLK8Xw2ac0blsDQpF4pkJxUc" rel="stylesheet" />
    <link href="/lib/animate.css/animate.css?v=IT6GQizZpVcaM1_L_mIiNAYVvZErMgfwewf1GGWXG_I" rel="stylesheet" />
    <link href="/css/materialize.css?v=ey-J3xahkqficOYUHVX3jexmzvRFrge9bmux4CQr1DQ" rel="stylesheet" />
    <link href="/css/Publicstyle.css?v=xhOiVjq-54ODzSIeHXoascHsEJm_n_bIHqZatpxnYhg" rel="stylesheet">
    <link href="/css/Comman.css?v=bcS6_IRqBsBcY1mS_iriWWanrYR0Scdo1ffk8rQGXwQ" rel="stylesheet" />
    <link href="/css/themes/all-themes.css?v=eGSl5zNTWrXYfUx_EJW9ksC3CUTUUxvxmPiA3aQDtQo" rel="stylesheet" />
    <link href="/view-resources/Views/Shared/_Layout.css?v=BLxBuNISlF2O5EBHWdsX039NvnIHy-GtcqeI_MbyIc0" rel="stylesheet" />
    <link href="/lib/enjoyhint/enjoyhint.css?v=rSxIyBbiAvx_48ZcFxbn2DNPCCgEc0FXa2Vb72enxk4" rel="stylesheet" />
    <link href="/lib/dropzone/dropzone.css?v=IQDlHJdeYZ4gMH87EuB1yEG7ujA7DSEkV_SWfACk8Rg" rel="stylesheet" />

    <!-- View specific styles -->
    
    <script type="text/javascript" nonce="c7f26c8w">
        // This is used to get the application's root path from javascript. It's useful if you're running application in a virtual directory under IIS.
        var abp = abp || {};
        abp.appPath = '/';

    </script>
    <style>
        .popover .popover-title {
            text-align: right;
            font-weight: bold;
        }
        .popover .popover-content {
            text-align: right;
            font-size: 14px;
            font-family: 'Almarai', sans-serif;
            color: black;
        }
       
    </style>
</head>
<body>
    <!-- Page Loader -->
    <div class="page-loader-wrapper">
        <div class="loader">
            <div class="preloader">
                <div class="spinner-layer pl-blue">
                    <div class="circle-clipper left">
                        <div class="circle"></div>
                    </div>
                    <div class="circle-clipper right">
                        <div class="circle"></div>
                    </div>
                </div>
            </div>
            <p>&#x628;&#x631;&#x62C;&#x627;&#x621; &#x627;&#x644;&#x625;&#x646;&#x62A;&#x638;&#x627;&#x631; ...</p>
        </div>
    </div>
    <!-- #END# Page Loader -->
    <!-- Overlay For Sidebars -->
    <div class="overlay"></div>
    <!-- #END# Overlay For Sidebars -->
    <!-- Search Bar -->
    <!-- Top Bar -->
    <nav class="navbar navbar-inverse naav" style="margin-bottom: 0;">
        <div class="container-fluid">
            <div class="navbar-header">
                <button type="button" class="navbar-toggle" data-toggle="collapse" data-target="#myNavbar">
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                </button>
            </div>
            <div class="collapse navbar-collapse rtl" id="navbar-collapse">
                <ul class="nav navbar-nav navbar-right">
                    <li><a href="/home/DrugSearch">&#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</a></li>
                        <li><a href="/Account/Login"><i class="fa fa-key"></i>&nbsp;&#x62A;&#x633;&#x62C;&#x64A;&#x644; &#x627;&#x644;&#x62F;&#x62E;&#x648;&#x644;</a></li>
                </ul>
                <ul class="nav navbar-nav navbar-left">
                    <li class="dropdown">
    <a href="javascript:void(0);" class="dropdown-toggle" data-toggle="dropdown" role="button">
        <i class="famfamfam-flags sa" title="&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;"></i>
        <span>&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</span>
        <b class="caret"></b>
    </a>
    <ul class="dropdown-menu pull-right">
                <li><a href="/AbpLocalization/ChangeCulture?cultureName=en"><i class="famfamfam-flags gb"></i> English</a></li>

    </ul>
</li>

                </ul>
            </div>
        </div>
    </nav>
    <section id="mainContent" class="content">
        <nav class="navbar naav" style="margin-bottom: 0;">
            <div class="container-fluid">
                <ul class="nav navbar-nav">
                    <li>
                        <a class="text-center" href="/">
                            <img src="/images/logo_sdi.png" style="margin: auto;" width="250">
                        </a>
                    </li>
                </ul>
                <div class="navbar-header navbar-toggle2 ">
                    <button type="button" class="navbar-toggle navbar-toggle2" data-toggle="collapse"
                            data-target="#myNavbar2">
                        <span class="icon-bar icon-bar2 "></span>
                        <span class="icon-bar icon-bar2"></span>
                        <span class="icon-bar icon-bar2"></span>
                    </button>
                </div>
                <div class="collapse navbar-collapse " id="myNavbar2">
                    <ul class="nav navbar-nav">
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover" data-placement="bottom" title="" data-content="موقع الكترونى يمكن شركات ووكلاء الادويه من رفع النشرات الممارس الصحى ونشرة معلومات المريض وصورة عبوة الدواء المعتمدة من الهيئة العامة للعذاء والدواء بهدف بناء مرجع وطنى للادوية المسجلة يمكن الرجوع له من قبل الممارس الصحى والمريض كمصدر موثوق للمعلومات الدوائية"
                               data-original-title="&#x645;&#x646; &#x646;&#x62D;&#x646;">
                                &#x645;&#x646; &#x646;&#x62D;&#x646;
                            </a>
                        </li>
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover"
                               data-placement="bottom"
                               title=""
                               data-content="&#x627;&#x630;&#x627; &#x643;&#x627;&#x646; &#x644;&#x62F;&#x64A;&#x643;&#x645; &#x645;&#x644;&#x627;&#x62D;&#x638;&#x627;&#x62A; &#x627;&#x648; &#x627;&#x642;&#x62A;&#x631;&#x627;&#x62D;&#x627;&#x62A; &#x64A;&#x631;&#x62C;&#x649; &#x627;&#x644;&#x62A;&#x648;&#x627;&#x635;&#x644; &#x639;&#x644;&#x649;   SDI@SFDA.GOV.SA"
                               data-original-title="&#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;">
                                &#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;
                            </a>
                        </li>

                    </ul>
                </div>
            </div>
        </nav>
        

<div class="col-xs-12">
    <div class="row text-center">
        <a href="/" class="btn bg-blue btn-lg m-b-10 hover-white">&#x628;&#x62D;&#x62B; &#x62C;&#x62F;&#x64A;&#x62F;</a>
    </div>
</div>
<div class="jumbotron" style="margin-bottom: 0px; background-color: white !important;">
    <h3 class="text-center" style="color: #57aabf; ">Search Results</h3>
    <hr width="20%" style="border-top: 3px solid #54ae90;">

    <br>
    <table class="table s-row">
        <thead style="margin-bottom: 30px !important">
                <tr>
                    <th id="M" style="color:white;">
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x627;&#x644;&#x645;&#x645;&#x627;&#x631;&#x633; &#x627;&#x644;&#x635;&#x62D;&#x64A;</a>
                    </th>
                    <th id="A" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</a>
                    </th>
                    <th id="E" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x627;&#x646;&#x62C;&#x644;&#x64A;&#x632;&#x64A;&#x629;</a>
                    </th>
                    <th id="f" class="active-tab" type='button'>
                        <a href="javascript:void(0)" style="color: white;">&#x635;&#x648;&#x631; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>
                    <th id="D" style="color:white; background-color: #47a4ba;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x628;&#x64A;&#x627;&#x646;&#x627;&#x62A; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>

                </tr>
        </thead>
    </table>
    <div id="D-div" class="box-data" style="display: block;">
        <div class="row">

<div class="modal-body rtl">
    <div class="tab-content">
        <div role="tabpanel" class="tab-pane m-r-60  animated fadeIn active" id="edit-user-details">
<div class="row clearfix">
                    <div class="col-lg-6 col-md-6 col-sm-6">
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="RegisterNumber">&#x631;&#x642;&#x645; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        0401244678
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="RegisterYear">&#x633;&#x646;&#x629; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        2018
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="TradeName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x62A;&#x62C;&#x627;&#x631;&#x64A;</label>
                                    <div class="form-line">
                                        LEROXO 8 MG FILM COATED TABLET
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="ScientificName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x639;&#x644;&#x645;&#x64A;</label>
                                    <div class="form-line">
                                        LORNOXICAM
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label " for="Strength">&#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        8
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="StrengthUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        mg
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="AdministrationRouteName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x625;&#x633;&#x62A;&#x639;&#x645;&#x627;&#x644;</label>
                                    <div class="form-line">
                                        Oral use
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PharmaceuticalFormName">&#x627;&#x644;&#x634;&#x643;&#x644; &#x627;&#x644;&#x635;&#x64A;&#x62F;&#x644;&#x627;&#x646;&#x64A;</label>
                                    <div class="form-line">
                                        Film-coated tablet
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Size">&#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="SizeUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageSize">&#x62D;&#x62C;&#x645; &#x627;&#x644;&#x639;&#x628;&#x648;&#x629;</label>
                                    <div class="form-line">
                                        20
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageTypeName">&#x627;&#x646;&#x648;&#x627;&#x639; &#x627;&#x644;&#x639;&#x628;&#x648;&#x627;&#x62A;</label>
                                    <div class="form-line">
                                        Blister
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="LegalStatusName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x635;&#x631;&#x641;</label>
                                    <div class="form-line">
                                        Prescription
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="ProductControlName">&#x62D;&#x627;&#x644;&#x629; &#x627;&#x644;&#x645;&#x631;&#x627;&#x642;&#x628;&#x629;</label>
                                    <div class="form-line">
                                        Uncontrolled
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="DrugTypeName">&#x646;&#x648;&#x639; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</label>
                                    <div class="form-line">
                                        Generic
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="ShelfLife">&#x645;&#x62F;&#x629; &#x627;&#x644;&#x635;&#x644;&#x627;&#x62D;&#x64A;&#x629; &#x628;&#x627;&#x644;&#x623;&#x634;&#x647;&#x631;</label>
                                    <div class="form-line">
                                        24
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="StorageConditionsName">&#x634;&#x631;&#x648;&#x637; &#x627;&#x644;&#x62A;&#x62E;&#x632;&#x64A;&#x646;</label>
                                    <div class="form-line">
                                        store below 30°c
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Price">&#x633;&#x639;&#x631; &#x627;&#x644;&#x62C;&#x645;&#x647;&#x648;&#x631; &#x628;&#x627;&#x644;&#x631;&#x64A;&#x627;&#x644;  ( &#x627;&#x644;&#x633;&#x639;&#x631; )</label>
                                    <div class="form-line">
                                        17.5
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Manufacture_NameEn" name="Manufacture.NameEn" value="UNITED PHARMACEUTICAL COMPANY" />
                                        <label class="form-label" for="Manufacture_NameEn">&#x627;&#x644;&#x645;&#x635;&#x646;&#x639;</label>
                                        <div class="form-line">
                                            UNITED PHARMACEUTICAL COMPANY
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Agent" name="Agent" value="[Agent 359]" />
                                        <label class="form-label">&#x627;&#x644;&#x648;&#x643;&#x64A;&#x644;</label>
                                        <div class="form-line">
                                            Cigalah Group
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <label class="form-label" for="Company_NameEn">&#x627;&#x644;&#x634;&#x631;&#x643;&#x629; &#x627;&#x644;&#x645;&#x633;&#x648;&#x642;&#x629;</label>
                                        <div class="form-line">
                                            UNITED PHARMACEUTICAL CO.
                                        </div>
                                    </div>
                                </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode1">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 1</label>
                                    <div class="form-line">
                                        M01AC05 
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode2">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 2</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                    </div>
                </div>
        </div>
    </div>
</div>

        </div>
    </div>
    <div id="E-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> SFDA PIL</span>
                <span style="font-size:small;">  (Patient Information Leaflet (PIL) are under review by Saudi Food and Drug Authority)</span>

            </div>
</div>


<div class="clearfix ltr">
    <div class="col-lg-12 col-md-12 col-sm-12 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="InventedNameEn">1. What this product is and what it is used for</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Pharmacotherapeutic group:<br />Leroxo&reg; F.C. Tablets &ldquo;Lornoxicam&rdquo; is a non-steroidal anti-inflammatory drug and antirheumatic drug (NSAID) of the oxicam class.</p><p><br />Therapeutic Indication<br />It is intended for short term relief of acute mild to moderate<br />pain and symptomatic relief of pain and inflammation in rheumatoid arthritis and osteoarthritis.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="form-group clearfix">
            <label style="float: left" class="h2" for="PrecautionsEn">2. What you need to know before you use this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><strong>a. Do not take Leroxo&reg; F.C. Tablets if you:</strong><br />&bull;Are allergic (hypersensitive) to Lornoxicams or any of the other ingredients.<br />&bull;Suffer from thrombocytopenia<br />&bull;Are hypersensitive to other NSAIDs including acetylsalicylic acid<br />&bull;Suffer from severe heart failure.<br />&bull;Suffer from gastro-intestinal bleeding, cerebrovascular bleeding or other bleeding disorders<br />&bull;Have a history of gastrointestinal bleeding or perforation, related to previous NSAIDs therapy<br />&bull;Suffer from an active or have a history of recurrent peptic ulcer<br />&bull;Suffer from severe liver impairment<br />&bull;Suffer from severe renal impairment<br />&bull;Are in the last three months of your pregnancy.</p><p><br /><strong>b. Take special care with Leroxo&reg; F.C. Tablets</strong><br />Talk to your doctor or pharmacist before taking Leroxo&reg; F.C. Tablets:</p><p>&bull;if you have impaired renal function<br />&bull;if you have a history of hypertension and/or heart failure as fluid retention and oedema<br />&bull;if you suffer from ulcerative colitis or Crohn&rsquo;s disease<br />&bull;if you have a history of bleeding tendency<br />If you suffer from blood coagulation disorder, impaired liver function, such as liver cirrhosis, are elderly or you will be treated with Leroxo&reg; F.C. Tablets for more than 3 months, your doctor may monitor you by laboratory test on a frequent basis.<br />If you are going to be treated with heparin or tacrolimus concomitantly with Leroxo&reg; F.C. Tablets, please inform your doctor about your current medicine.<br />Leroxo&reg; F.C. Tablets should not be used concomitantly with other NSAIDs such as acetylsalicylic acid, ibuprofen and COX-2 inhibitors. Ask your doctor or pharmacist if you are uncertain.<br />If you experience any unusual abdominal symptoms such as abdominal bleeding, skin reactions such as skin rash, mucosal lesions or other signs of hypersensitivity, you should stop taking Leroxo&reg; F.C. Tablets and contact you doctor immediately.<br />Medicines such as Leroxo&reg; F.C. Tablets may be associated with a small increased risk of heart attack (&ldquo;myocardial infarction&rdquo;) or stroke. Any risk is more likely with high doses and prolonged treatment. Do not exceed the recommended dose of duration of treatment.<br />If you have heart problems, previous stroke or think that you might be at risk of these conditions (for example if you have high blood pressure, diabetes or high cholesterol or are a smoker) you should discuss your treatment with your doctor or pharmacist.</p><p><br /><strong>c. Taking other medicines, herbal or dietary supplements</strong><br />Please tell your doctor or pharmacist if you are taking or have recently taken any other medicines, including medicines obtained without a prescription.<br />Leroxo&reg; F.C. Tablets may interfere with other medicines.<br />Particular care should be taken if you are receiving any of the following substances:<br />- Cimetidine<br />- Anticoagulant as heparin, phenprocoumon<br />- Corticosteroids<br />- Methotrexate<br />- Lithium<br />- Immunosuppressive agents as Ciclosporine, tacrolimus<br />- Heart medicine as digoxin, ACE-inhibitors, beta-adrenergic blockers<br />- Diuretics<br />- Quinolone antibiotics<br />- Anti-platelet agents<br />- NSAIDs as ibuprofen, acetylsalicylic acids<br />- SSRI<br />- Sulphonylurea<br />- Inducer and inhibitors of CYP2C9-isoenzymes</p><p><br /><strong>d. Pregnancy and breast-feeding</strong><br />Ask your doctor or pharmacist for advice before taking any medicine.<br />Leroxo&reg; F.C. Tablets should not be taken during the first six months of pregnancy and by breast-feeding women.<br />You must not take Leroxo&reg; F.C. Tablets during the&nbsp;last three months of your pregnancy.<br />The use of Leroxo&reg; F.C. Tablets may impair fertility and is not recommended in women attempting to conceive. In women who have difficulties conceiving, or who are undergoing investigation of infertility, withdrawal of Leroxo&reg; F.C. Tablets should be considered.</p><p><strong>e. Driving and using machines</strong><br />No has no or negligible influence on the ability to drive or use machinery.</p><p><strong>f. Important information about some of the ingredients of Leroxo&reg; F.C. Tablets</strong><br />Leroxo&reg; F.C. Tablets contain lactose monohydrate.<br />If you have been told by your doctor that you have an intolerance to some sugars, contact your doctor before taking the medicinal product</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="AdministrationRoutesEn">3. How to use this product.</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Always take Leroxo&reg; F.C Tablets exactly as your doctor has told you. You should check with your doctor or pharmacist if you are not sure.</p><p><br />Adults: The usual dose is 8-16 mg divided into 2 or 3 doses. The maximum recommended dose is 16 mg daily.<br />Leroxo&reg; F.C. Tablets is not recommended for use in children and adolescents below age 18 due to lack of data<br />Leroxo&reg; F.C. Tablets are supplied for oral use and should be taken before meals with a sufficient quantity of liquid. Concomitant intake of food may reduce the uptake of the medicinal product</p><p><br /><strong>a. If you take more Leroxo&reg; F.C. Tablets than you should</strong><br />Please contact your doctor or the pharmacist if you have taken more Leroxo&reg; F.C. Tablets than prescribed.<br />In case of an overdose the following symptoms may be expected:<br />Nausea, vomiting, cerebral symptoms (dizziness, disturbances in vision).</p><p><strong>b. If you forget to take Leroxo&reg; F.C. Tablets</strong><br />Do not take a double dose to make up for a forgotten tablet.<br />If you have any further questions on the use of this product, ask your doctor or pharmacist.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsEn">4. Possible side effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Like all medicines, Lornoxicam can cause side effects, although not everybody gets them.<br />Medicines such as Lornoxicam may be associated with a small increased risk of heart attack (&ldquo;myocardial infarction&rdquo;) or stroke.<br />The most common side effects of Lornoxicam include nausea, dyspepsia, indigestion, abdominal pain, vomiting, and diarrhoea.</p><p><strong>Common (less than 1 in 10, but more than 1 in 100 patient&rsquo;s treated)</strong><br />Mild and transient headache, dizziness, nausea, abdominal pain, dyspepsia, diarrhoea, vomiting.</p><p><strong>Uncommon (less than 1 in 100, but more than 1 in 1000 patient&rsquo;s treated)</strong><br />Anorexia, insomnia, depression, conjunctivitis, vertigo, tinnitus, palpitations, tachycardia, flushing, constipation, flatulence, eructation, dry mouth, gastritis, gastric ulcer, abdominal pain upper, duodenal ulcer, mouth ulceration, increase in liver function tests, SGPT (ALT) or SGOT (AST), rash, pruritus, hyperhidrosis, rash erythematous, urticaria, alopecia, arthralgia, rheumatoid arthritis, osteoarthritis, malaise,&nbsp;face oedema, weight changes, oedema, rhinitis.</p><p><strong>Rare (less than 1 in 1000, but more than 1 in 10.000 patents treated)</strong><br />Pharyngitis, anaemia, thrombocytopenia, leucopoenia, hypersensitivity, confusion, nervousness, agitation, somnolence,<br />paresthesia, dysgeusia, tremor, migraine, visual disturbances, hypertension, hot flush, hemorrhage, hematoma,<br />dyspnoea, cough, melena, hematemesis, stomatitis, esophagitis, gastroesophageal reflux, dysphagia, aphthous stomatitis, glossitis, hepatic function abnormal, dermatitis, bone pain, muscle spasms, myalgia, nocturia, micturition disorders, asthenia, prolonged bleeding time, purpura, bronchospasm, increase in blood urea nitrogen and creatinine levels, perforated peptic ulcer</p><p><strong>Very rare (less than 1 in 10.000 patients treated)</strong><br />Hepatocellular damage, ecchymosis, oedema and bullous reactions, Stevens-Johnson syndrome, Toxic epidermal necrolysis.</p><p>If any of the side effects gets serious, or if you notice any side effects not listed in this leaflet, please tell your doctor or pharmacist.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsEn">5. How to store this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>-Keep out of the reach and sight of children.<br />-Do not store above 30&deg; C.<br />-Do not use Leroxo&reg; F.C. Tablets after the expiry date (Exp. Date) which is stated on the outer pack. The expiry date refers to the last day of that month.<br />-Medicines should not be disposed of via wastewater or household waste. Ask your pharmacist how to dispose of medicines no longer required. These measures will help to protect the environment.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. Further information</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsEn">a. What this product contains</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>The active substance is Lornoxicam.<br />Leroxo&reg; 8 mg F.C. Tablets: Each film coated tablet contains<br />8 mg Lornoxicam<br />The other ingredients are:<br />Lactose regular, Microcrystalline Cellulose, Povidone K30, Crosscarmellose Sodium, Magnesium Stearate &amp; Opadry White</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsEn">b. What this product looks like and contents of the pack</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                Film Coated Tablets.
Physical Description: White oval shaped tablets embossed with U10.
Leroxo® Tablets are packed in blisters of PVC /PVDC/ Aluminum foil, in carton box with a multi folded leaflet.
Pack size: 10 F.C Tablets; (10 F.C. tablets /blister, 1 blister/ pack) or 20 F.C Tablets; (10 F.C. tablets /blister, 2 blisters/ pack).
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingEn">c. Marketing Authorization Holder and Manufacturer</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>The United Pharmaceutical Mfg. Co. Ltd.<br />P.O. Box 69, Amman 11591-Jordan<br />Tel: + 962 (6) 416 2901<br />Fax: + 962 (6) 416 2905<br />E-mail: upm_info@mspharma.com</p><p>For any information about this medicinal product, please contact the local representative of the Marketing Authorization<br />Holder:<br />Cigalah Group</p><p>P.O. Box 19435, Jeddah 21435 -KSA<br />Tel: +966126136740<br />Fax: + 96626148458<br />E-mail: ihamidaddin@cigalah.com.sa</p><p><br />&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteEn">d. This leaflet was last revised in {MM/YYYY}</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                This leaflet was last approved in 11/2017; version number: M3-14-0922
            </div>
        </div>
    </div>
</div>    </div>
    <div id="A-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> نشرة الدواء تحت مراجعة الهيئة العامة للغذاء والدواء</span>
                <span style="font-size:small;">  (اقرأ هذه النشرة بعناية قبل البدء في استخدام هذا المنتج لأنه يحتوي على معلومات مهمة لك)</span>
            </div>
    <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr">

    </div>

</div>
<div class="clearfix rtl">
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="InventedNameAr">1. ما ھو هذا المستحضر وماھي دواعي استعماله</label>
        </div>
        <div class="form-group clearfix" style="float: right">
            <br />
            <p>المجموعة العلاجية:</p><p>ليروكسو أقراص مغلفة &laquo;لورنوكسيكام&raquo; هو مضاد التهاب لاستيرويدي NSAID ويمتلك خصائص مضادة للروماتيزم، ينتمي إلى فئة الأوكسيكام.</p><p><br />دواعي الاستعمال:</p><p>يوصف لتخفيف أعراض الألم والالتهاب الخفيف الى المتوسط في التهاب المفاصل الروماتيزمي والتهاب المفاصل على المدى القصير.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="PrecautionsAr">2. ما الذي يجب عليك معرفته قبل استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p><strong>أ. لا تأخذ ليروكسو أقراص مغلفة إذا كنت:</strong></p><p>&bull;تعاني من الحساسية فرط الحساسية لمادة لورنوكسيكام أو لأي من المكونات الأخرى.</p><p>&bull;تعاني من نقص الصفيحات</p><p>&bull;تعاني من فرط الحساسية لمضادات الالتهاب اللاستيرويدية الأخرى بما في ذلك الاسبرين.</p><p>&bull;تعاني من فشل القلب شديد.</p><p>&bull;تعاني من نزيف هضمي، نزيف دماغي أو غيرها من الاضطرابات النزيفة</p><p>&bull;لديك تاريخ مسبق لحدوث نزيف هضمي أو انثقاب، بسبب العلاج المسبق بالمسكنات.</p><p>&bull;تعاني من قرحة حالية أو لديك تاريخ مسبق للاصابة بقرحة هضمية متكررة.</p><p>&bull;تعاني من ضعف الكبد الشديد</p><p>&bull;تعاني من القصور الكلوي الشديد</p><p>&bull;في الأشهر الثلاثة الأخيرة من الحمل.</p><p>&nbsp;</p><p><strong>ب. اتخاذ عناية خاصة مع ليروكسو أقراص مغلفة</strong></p><p>تحدث إلى طبيبك أو الصيدلي قبل أخذ ليروكسو أقراص مغلفة</p><p>&bull; إذا كان لديك ضعف في وظائف الكلى</p><p>&bull; إذا كان لديك تاريخ مسبق لارتفاع ضغط الدم و / أو قصور القلب وايضا احتباس السوائل والوذمة</p><p>&bull; إذا كنت تعاني من التهاب القولون التقرحي أو مرض كراون</p><p>&bull; إذا كان لديك تاريخ مسبق لميل حدوث النزيف إذا كنت تعاني من اضطراب في تخثر الدم، ضعف وظائف الكبد، مثل تليف الكبد، وكبر السن أو تم علاجك باستعمال ليروكسو أقراص مغلفة لأكثر من 3 أشهر، يجب على طبيبك مراقبتك عن طريق اجراء الفحوص المخبرية بشكل متكرر.</p><p>إذا كنت ستعالج مع الهيبارين أو تاكروليموس بالتزامن مع ليروكسو أقراص مغلفة، يرجى إبلاغ الطبيب عن الدواء الحالي.</p><p>لا ينبغي أن تستخدم ليروكسو أقراص مغلفة بالتزامن مع مضادات الالتهاب اللاستيرويدية الأخرى مثل الاسبرين، ايبوبروفين ومثبطات كوكس-2.</p><p>اسأل طبيبك أو الصيدلي إذا كنت غير متأكد.</p><p>إذا واجهت أي أعراض غير طبيعية في البطن مثل نزيف البطن، وردود فعل جلدية مثل الطفح الجلدي، والآفات المخاطية أو غيرها من علامات فرط الحساسية، يجب التوقف عن تناول ليروكسو أقراص مغلفة والاتصال بالطبيب فورا.</p><p>قد يترافق مع الأدوية مثل ليروكسو أقراص مغلفة زيادة خطر الاصابة بأزمة قلبية صغيرة &laquo;احتشاء عضلة القلب&raquo; أو السكتة الدماغية.</p><p>إن الخطر يكون أكثر احتمالا مع استعمال جرعات عالية والعلاج لفترات طويلة.</p><p>لا تتجاوز الجرعة الموصى بها من مدة العلاج. إذا كان لديك مشاكل في القلب أو سكتة دماغية سابقة أو تعتقد بأنك قد تكون في خطر لهذه الحالات على سبيل المثال إذا كان لديك ارتفاع ضغط الدم أو&nbsp; السكري أو ارتفاع الكولسترول أو كنت مدخن يجب عليك مناقشة العلاج الخاص بك مع الطبيب أو الصيدلي.</p><p>&nbsp;</p><p><strong>ج. تناول أدوية أخرى، مكملات عشبية أو غذائية </strong></p><p>يرجى إخبار الطبب أو الصيدلي إذا كنت تتناول أو تناولت مؤخرا أدوة أخرى، بما في ذلك الأدوة التي تم الحصول عليها بدون وصفة طبة.</p><p>قد تتداخل ليروكسو أقراص مغلفة مع أدوية أخرى.</p><p>وينبغي إيلاء عناية خاصة إذا كنت تتلقى أي من المواد التالية:</p><p>- سيميتيدين</p><p>- مضادات التخثر مثل الهيبارين، فينبروكومون</p><p>- كورتيكوستيرويد</p><p>- ميثوتريكسيت</p><p>- ليثيوم</p><p>- العوامل المثبطة للمناعة مثل السيكلوسبورين، تاكروليموس</p><p>- أدوية القلب مثل ديجوكسين، مثبطات الإنزيم المحول للأنجيوتنسين ، حاصرات مستقبلات بيتا الأدرينالية</p><p>- مدرات البول</p><p>- المضادات الحيوية من مجموعة الكينولون</p><p>- العوامل المضادة لتكدس الصفائح الدموية</p><p>- المسكنات مثل ايبوبروفين، الاسبرين</p><p>- مثبطات إعادة امتصاص السيروتونين الانتقائية</p><p>- سولفونيلوريا</p><p>- محفزات ومثبطات متشابهات انزيم CYP2C9</p><p>&nbsp;</p><p><strong>د. الحمل والرضاعة الطبيعية</strong></p><p>استشر طبيبك أو الصيدلي قبل تناول أي دواء. لا ينبغي أن تأخذ ليروكسو أقراص مغلفة خلال الأشهر الستة الأولى من الحمل ومن قبل النساء المرضعات. يجب عدم أخذ ليروكسو أقراص مغلفة خلال الأشهر الثلاثة الأخيرة من الحمل.</p><p>إن استخدام ليروكسو أقراص مغلفة قد يضعف الخصوبة وليس من المستحسن تناوله في النساء اللواتي يحاولن الحصول على حمل.</p><p>في النساء اللواتي لديهن صعوبات في حدوث الحمل، أو اللواتي يخضعن لعلاج العقم، ينبغي النظر في التوقف عن استخدام ليروكسو أقراص مغلفة</p><p>&nbsp;</p><p><strong>ه. القيادة واستخدام الآلات </strong></p><p>لا يوجد لديه أي تأثير يذكر على القدرة على القيادة أو استخدام الآلات.</p><p>&nbsp;</p><p><strong>و. معلومات هامة عن بعض مكونات ليروكسو أقراص مغلفة</strong></p><p>تحتوي ليروكسو أقراص مغلفة على لاكتوز مونوهيدرات. إذا قيل لك من قبل طبيبك أن لديك تعصب لبعض السكريات، اتصل بطبيبك قبل تناول هذا المنتج الطبي.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            https://localhost:44358/Dashboard
            <label class="h2" for="AdministrationRoutesAr">3. ماھي طريقة استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p>دائما تناول ليروكسو أقراص مغلفة تماما كما قال لك الطبيب أو الصيدلي.</p><p>تحقق مع طبيبك أو الصيدلي إذا كنت غير متأكد.</p><p>&nbsp;</p><p>البالغين: الجرعة الاعتيادية هي 8-16 ملغم مقسمة إلى 2 أو 3 جرعات. الجرعة القصوى الموصى بها هي 16 ملغم يوميا.</p><p>لا ينصح باستخدام ليروكسو أقراص مغلفة في الأطفال والمراهقين دون سن 18 بسبب عدم وجود معلومات.</p><p>يتم تزويد ليروكسو أقراص مغلفة للاستخدام عن طريق الفم وينبغي أن تؤخذ قبل وجبات الطعام مع كمية كافية من السوائل.</p><p>قد يقل امتصاص المنتج الطبي إذا ما تم تناوله مع الطعام.</p><p>&nbsp;</p><p><strong>أ. إذا تناولت ليروكسو أكثر مما يجب</strong></p><p>يرجى الاتصال بالطبيب أو الصيدلي إذا كنت قد تناولت ليروكسو أقراص مغلفة أكثرمن المنصوص عليه. قد يتوقع حدوث الأعراض التالية في حالة فرط الجرعة: الغثيان والقيء، والأعراض الدماغية الدوخة، واضطرابات في الرؤية.</p><p><strong>ب. إذا نسيت تناول ليروكسو أقراص مغلفة</strong></p><p>لا تأخذ جرعة مضاعفة لتعويض القرص المنسي. إذا كان لديك أي أسئلة أخرى حول استخدام هذا المنتج، اسأل طبيبك أو الصيدلي</p><p>&nbsp;</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsAr">4. الأعراض الجانبية المحتملة</label>
        </div>
        <div class="m-r-60">
            <p>مثل جميع الأدوية، يمكن للورنوكسيكام أن يتسبب في إحداث آثار جانبية، على الرغم انها لا تصيب الجميع.</p><p>قد ترتبط الأدوية مثل لورنوكسيكام مع زيادة خطر الاصابة بأزمة قلبية صغيرة &laquo;احتشاء عضلة القلب&raquo; أو السكتة الدماغية.</p><p>وتشمل الآثار الجانبية الأكثر شيوعا من لورنوكسيكام الغثيان وسوء الهضم وعسر الهضم وآلام البطن والقيء والإسهال.</p><p><strong>شائعة </strong>أقل من 1 في كل 10، ولكن أكثر من 1 في كل 100 مريض تم علاجه صداع معتدل وعابر، الدوخة، الغثيان، وآلام في البطن، سوء الهضم، الإسهال والتقيؤ.</p><p><strong>غير شائعة</strong> أقل من 1 في كل 100، ولكن أكثر من 1 في كل 1000 مريض تم علاجه فقدان الشهية، الأرق، الاكتئاب، التهاب الملتحمة، الدوار، طنين، الخفقان، عدم انتظام دقات القلب، احمرار، إمساك، انتفاخ البطن، تجشؤ، جفاف الفم، التهاب المعدة، قرحة المعدة، آلام في البطن من الجهه العلوية، قرحة الاثني عشر، تقرح الفم، ارتفاع في فحوص وظائف الكبد ALT أو &nbsp;، AST طفح جلدي، حكة، فرط التعرق، حمامى جلدية، شرى، ثعلبة، ألم مفصلي،&nbsp;التهاب المفاصل الروماتيزمي، هشاشة العظام، الشعور بالضيق، وذمة الوجه، تغيرات في الوزن، وذمة، التهاب الأنف.</p><p><strong>نادرة </strong>أقل من 1 في كل 1000، ولكن أكثر من 1 في كل 10.000 مريض تم علاجه التهاب البلعوم، فقر الدم، نقص الصفيحات، نقص في عدد كريات الدم البيضاء، فرط الحساسية، الارتباك، العصبية، اهتياج، نعاس، تنمل، اضطراب التذوق، هزة، صداع نصفي، اضطرابات بصرية، ارتفاع ضغط الدم، هبات ساخنة، نزيف، ورم دموي، ضيق في التنفس، سعال، برازدموي، قيء دموي، التهاب المريء، ارتجاع مرئي، عسر البلع، التهاب الفم القلاعي، التهاب اللسان، خلل في وظيفة الكبد، التهاب الجلد، آلام في العظام، تشنج العضلات، ألم عضلي، كثرة التبول، اضطرابات في التبول، وهن، اطالة في وقت النزيف، فرفرية، تشنج قصبي، زيادة في النيتروجين واليوريا في الدم وارتفاع مستويات الكرياتينين، انثقاب القرحة الهضمية</p><p><strong>نادرة جدا</strong> أقل من 1 في كل 10.000 مريض تم علاجه<br />تلف الكبد، كدمات، وذمة وردود الفعل الفقاعية، متلازمة ستيفنز جونسون، انحلال البشرة السمي. إذا أصبحت أي من الاعراض الجانبية خطيرا، أو إذا لاحظت أي آثار جانبية غير مدرجة في هذه النشرة، يرجى إخبار الطبيب أو الصيدلي بذلك.</p><p>&nbsp;</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsAr">5. طريقة تخزين المستحضر</label>
        </div>
        <div class="m-r-60">
            <p>-احفظ الدواء بعيدا عن متناول و نظر الأطفال.</p><p>- يحفظ على درجة حرارة الغرفة لا تتجاوز&ordm;30م.</p><p>-لا تستعمل ليروكسو أقراص مغلفة بعد انقضاء تاريخ الصلاحية المدون على علبة الكرتون بعد كلمة .Exp يشير تاريخ الصلاحية الى اليوم الأخير من الشهر المذكور. -لا ينبغي أن يتم التخلص من الأدوية من خلال مياه الصرف الصحي أو النفايات المنزلية.</p><p>اسأل الصيدلي عن كيفية التخلص من الأدوية التي لم تعد لازمة. ومن شأن هذه التدابير أن تساعد على حماية البيئة.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: right">6. معلومات أخرى</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsAr">أ‌. على ماذا يحتوي هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p>المادة الفعالة هي لورنوكسيكام.</p><p>ليروكسو 8 ملغم أقراص مغلفة: كل قرص مغلف يحتوي على لورنوكسيكام 8 ملغم.</p><p>المكونات الأخرى هي: لاكتوز عادي، ميكروكريستالين سليولوز، بوفيدون ك 30 ، كروسكارميلوز الصوديوم، إستارات المغنيسيوم وأوبادراي أبيض.</p><p>&nbsp;</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsAr">ب‌. كيف يبدو شكل هذا المستحضر وماهي محتويات العلبة</label>
        </div>
        <div class="m-r-60">
            <p>أقراص مغلفة.</p><p>الوصف المادي:</p><p>أقراص بيضاء بيضاوية منقوشة ب .U10يعبأة ليروكسو أقراص مغلفة في أشرطة ألومنيوم من مادة / PVCPVDC، في علبة كرتون مع نشرة مطوية. حجم العبوة: 10 أقراص مغلفة. 10 أقراص مغلفة / شريط، شريط / العبوة أو20 قرص مغلف؛ 10 أقراص مغلفة / شريط، شريطين / العبوة.</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingAr">ت‌. الشركة المصنعة ومالك حق التسويق</label>
        </div>
        <div class="m-r-60">
            <p>مالك رخصة التسويق :</p><p>الشركة المتحدة لصناعة الأدوية ذ.م.م</p><p>ص.ب. 69، عمان 11591- الأردن</p><p>هاتف: 2901 416 6 962+</p><p>فاكس: 2905 416 6 962+</p><p>البريد الإلكتروني: upm_info@mspharma.com</p><p>&nbsp;</p><p>لأي معلومات عن هذا الدواء، يرجى الاتصال بالممثل المحلي للشركة حاملة رخصة التسويق:</p><p>مجموعة سيغالا</p><p>ص ب 19435، جدة 21435-السعودية</p><p>الهاتف: +966126136740</p><p>فاكس: + 96626148458</p><p>البريد الإلكتروني: ihamidaddin@cigalah.com.sa</p><p>&nbsp;</p><p>&nbsp;</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteAr">ث‌. تمت مراجعة هذه النشرة في التاريخ الذي تمت فيه مراجعة النشرة بالشهر والسنة</label>
        </div>
        <div class="m-r-60">
             تم الموافقة على هذه النشرة بتاريخ 11/2017؛ رقم النسخة :M3-14-0922

        </div>
    </div>
</div>
    </div>
    <div id="M-div" class="box-data">


    <div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr"><i class="fa fa-info-circle"></i>&nbsp;Read this leaflet carefully before you start using this product as it contains important information for you</div>
    </div>
<div class="row clearfix ltr">

    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="MedicinalName">1. NAME OF THE MEDICINAL PRODUCT </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                LEROXO® 8mg Film Coated Tablets
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="QualitativeQuantitativeComposition">2. QUALITATIVE AND QUANTITATIVE COMPOSITION </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                ﻿Material Name 	Function 	Amount (mg)/one tablet	 
Lornoxicam 	Active material 	8.0* 	 
Lactose Regular 	Diluent 	90.0 	 
Microcrystalline Cellulose 	Diluent 	87.0* 	 
Povidone K30 	Binder 	6.0 	 
Crosscarmellose Sodium 	Disintegrant 	8.0 	 
Magnesium stearate 	Lubricant 	1.0 	 
Isopropanol 	Granulation solvent 	Q.S** 	 
Total After Coating 	200.0 	 
Opadry White OY_L 28900 	Film coating material 	10.0 	 
Total after coating 	210 	 

*actual quantity depends on the potency and water content of the API.
** evaporate during drying process.
For a full list of excipients, see section 6.

            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="DosageForm">3. PHARMACEUTICAL FORM </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Film Coated Tablets
LEROXO® 8 mg F.C. Tablets: White oval shaped tablets embossed with U10.
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">4. CLINICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="TherapeuticIndications">4.1 Therapeutic Indications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>LEROXO&reg; F.C. Tablets is indicated for:<br />- Short-term relief of acute mild to moderate pain<br />- Symptomatic relief of pain and inflammation in osteoarthritis.<br />- Symptomatic relief of pain and inflammation in rheumatoid arthritis</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PosologyAndMethodAdministration">4.2 Posology And Method Administration</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><strong>Route of administration: Orally.<br />Posology</strong><br />For all patients the appropriate dosing regimen should be based upon individual response to treatment.<br />Pain<br />8-16 mg lornoxicam daily divided into 2 or 3 doses. Maximum recommended daily dose is 16 mg.</p><p><u>Osteoarthritis and rheumatoid arthritis</u><br />Initial recommended dose is 12 mg lornoxicam daily divided into 2 or 3 doses. Maintenance dose should not exceed 16 mg lornoxicam daily.<br /><strong>Additional information on special populations</strong><br /><u>Children and adolescents</u><br />Lornoxicam is not recommended for use in children and adolescents below age 18 because of a lack of data on safety and efficacy.<br /><u>Elderly</u><br />No special dosage modification is required for elderly patients above age 65 unless renal or hepatic function is impaired. Lornoxicam should be administered with precaution as gastrointestinal adverse effects are less well tolerated in this group.<br /><u>Renal impairment</u><br />For patients with mild to moderate renal impairment the maximum recommended daily dose is 12 mg divided in 2 or 3 doses.<br /><u>Hepatic impairment</u><br />For patients with moderate hepatic impairment the maximum recommended daily dose is 12 mg divided in 2 or 3 doses.<br />Undesirable effects may be minimized by using the lowest effective dose for the shortest duration necessary to control symptoms.<br />&nbsp;</p><p><strong>Method of Administration</strong><br />LEROXO&reg; film-coated tablets are supplied for oral administration and should be taken with a sufficient quantity of liquid.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Contraindications">4.3 Contraindications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                - Hypersensitivity to the active substance or any of the excipients
- Thrombocytopenia
- Hypersensitivity (symptoms like asthma, rhinitis, angioedema or urticaria) to other NSAIDs including acetylsalicylic acid
- Severe heart failure
- Gastro-intestinal bleeding, cerebrovascular bleeding or other bleeding disorders
- History of gastrointestinal bleeding or perforation, related to previous NSAIDs therapy
- Active or history of recurrent peptic ulcer/hemorrhage (two or more distinct episodes of proven ulceration or bleeding)
- Severe hepatic impairment
- Severe renal impairment (Serum creatinine > 700 μmol/l)
- The third trimester of pregnancy.
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialWarnings">4.4. Special warnings and precautions for use</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>For the following disorders, lornoxicam should only be administered after careful risk-benefit assessment:</p><p>- Renal impairment: Lornoxicam should be administered with precaution in patients with mild (serum creatinine 150-300 &mu;mol/l) to moderate (serum creatinine 300 &ndash; 700 &mu;mol/l) renal impairment due to dependency on renal prostaglandins for maintenance of renal blood flow. Treatment with lornoxicam should be discontinued if renal function deteriorates during treatment.<br />- Renal functions should be monitored in patients who undergo major surgery, with cardiac failure, receiving treatment with diuretics, receiving concomitant treatment with drugs that are suspected to or known to be able to cause kidney damage.<br />- Patients with blood coagulation disorders: Careful clinical monitoring and laboratory assessment is recommended (e.g. APTT).<br />- Hepatic impairment (e.g. liver cirrhosis): Clinical monitoring and laboratory assessments at regular intervals should be considered in patients with hepatic impairment as accumulation of lornoxicam (increase in AUC) may occur after treatment with daily doses of 12-16 mg. Apart from that, hepatic impairment does not seem to affect pharmacokinetic parameters of lornoxicam as compared to healthy subjects.<br />- Long term treatment (longer than 3 months): Regular laboratory assessments of hematology (hemoglobin), renal functions (creatinine) and liver enzymes are recommended.<br />- Elderly patients above 65 years: Monitoring of renal and hepatic function is recommended. Precaution is advised in elderly postoperative patients.<br />The use of lornoxicam with concomitant NSAIDs including cyclooxygenase-2 selective inhibitors should be avoided.<br />Undesirable effects may be minimized by using lowest effective dose for the shortest duration necessary to control symptoms.<br />Gastrointestinal bleeding, ulceration and perforation: GI bleeding, ulceration or perforation, which can be fatal, has been reported with all NSAIDs at anytime during treatment, with or without warning symptoms or a previous history of serious GI events.<br />The risk of GI bleeding, ulceration or perforation is higher with increasing NSAID doses, in patients with a history of ulcer, particularly if complicated with hemorrhage or perforation, and in the elderly. These patients should commence treatment on the lowest dose available. Combination therapy with protective agents (e.g. misoprostol or proton pump inhibitors) should be considered for these patients, and also for patients requiring concomitant low dose acetylsalicylic acid or other active substances likely to increase gastrointestinal risk. Clinical monitoring at regular intervals is recommended.<br />Patients with a history of GI toxicity, particularly when elderly, should report any unusual abdominal symptoms (especially GI bleeding) particularly in the initial stages of treatment.<br />Caution should be advised in patients receiving concomitant medicinal products, which could increase the risk of ulceration or bleeding, such as oral corticosteroids, anticoagulants such as warfarin, selective serotonin-reuptake inhibitors or anti-platelet agents such as acetylsalicylic acid.<br />When GI bleeding or ulceration occurs in patients receiving lornoxicam, the treatment should be withdrawn.<br />NSAIDs should be given with care to patients with a history of gastrointestinal disease (ulcerative colitis, Crohn&#39;s disease) as their condition may be exacerbated.</p><p>The elderly have an increased frequency of adverse reactions to NSAIDs especially gastrointestinal bleeding and perforation, which may be fatal.<br />Caution is required in patients with a history of hypertension and/or heart failure, as fluid retention and edema have been reported in association with NSAID therapy.<br />Appropriate monitoring and advice are required for patients with a history of hypertension and/or mild to moderate congestive heart failure, as fluid retention and edema have been reported in association with NSAID therapy.<br />Clinical and epidemiological data suggest that use of some NSAIDs (particularly at high doses and in long term treatment) may be associated with a small increased risk of arterial thrombotic events (for example myocardial infarction or stroke). There are insufficient data to exclude such a risk for lornoxicam.<br />Patients with uncontrolled hypertension, congestive heart failure, established ischemic heart disease, peripheral arterial disease, and/or cerebrovascular disease should only be treated with Lornoxicam after careful consideration. Similar consideration should be made before initiating longer-term treatment of patients with risk factors for cardiovascular disease (e.g. hypertension, hyperlipidemia, diabetes mellitus, smoking).<br />Concomitant treatment with NSAIDs and heparin in the context of a spinal or epidural anesthesia increases the risk of spinal/epidural hematoma.<br />Serious skin reactions, some of them fatal, including exfoliative dermatitis, Stevens-Johnson syndrome, and toxic epidermal necrolysis, have been reported very rarely in association with the use of NSAIDs. Patients appear to be at highest risk of these reactions early in the course of therapy, the onset of the reaction occurring in the majority of cases within the first month of treatment. Lornoxicam should be discontinued at the first appearance of skin rash, mucosal lesions, or any other sign of hypersensitivity.<br />Caution is required if administered to patients suffering from, or with a previous history of, bronchial asthma since NSAIDs have been reported to precipitate bronchospasm in such patients.<br />In patients with systemic lupus erythematosus (SLE) and mixed connective tissue disorders there may be an increased risk of aseptic meningitis.<br />Lornoxicam reduces platelet aggregation and prolongs bleeding time and consequently care should be taken when administering to patients with increased bleeding tendency.<br />Concomitant treatment of NSAIDs and tacrolimus may increase the risk of nephrotoxicity owing to reduced synthesis of prostacyclin in the kidney. Renal function must therefore be monitored closely in patients receiving combination therapy.<br />As with most NSAIDs occasional increase in serum transaminases level, increase in serum bilirubin or other liver function parameters, as well as increases in serum creatinine and blood urea nitrogen as well as other laboratory abnormalities have been reported. Should any such abnormality prove significant or persist the administration of lornoxicam should be stopped and appropriate investigations prescribed.<br />This medicinal product contains lactose. Patients with rare hereditary problems of galactose intolerance, the Lapp lactase deficiency or glucose-galactose malabsorption should not take this medicine.</p><p>The use of lornoxicam, as with any drug known to inhibit cyclooxygenase/ prostaglandin synthesis, may impair fertility and is not recommended in women attempting to conceive. In women who have difficulties conceiving or who are undergoing investigation of infertility, withdrawal of lornoxicam should be considered.<br />Exceptionally, varicella can be at the origin of serious cutaneous and soft tissues infectious complications.<br />To date, the contributing role of NSAIDs in the worsening of these infections cannot be ruled out. Thus, it is advisable to avoid use of lornoxicam in case of varicella.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="InteractionsOtherMedicines">4.5. Interactions with other medicinal products</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Concomitant administration of lornoxicam and:<br />- Cimetidine: Increased plasma concentrations of lornoxicam. (No interaction between lornoxicam and ranitidine, or lornoxicam and antacids has been demonstrated).<br />- Anti-coagulants: NSAIDs may enhance the effects of anti-coagulants, such as warfarin. Careful monitoring of INR should be undertaken.<br />- Phenprocoumon: Decreased effect of phenprocoumon treatment.<br />- Heparin: NSAIDs increase the risk of spinal or epidural hematoma when given concomitantly to heparin in the context of spinal or epidural anesthesia.<br />- ACE inhibitors: The antihypertensive effect of the ACE inhibitor may decrease.<br />- Diuretics: Decreased diuretic and antihypertensive effect of loop diuretics, thiazide diuretics, and potassium sparing diuretics.<br />- Beta-adrenergic blockers: Decreased antihypertensive efficacy.<br />- Angiotensin II receptor blocker: Decreased antihypertensive efficacy.<br />- Digoxin: Decreased renal clearance of digoxin.<br />- Corticosteroids: Increased risk of gastrointestinal ulceration or bleeding.<br />- Quinolone antibiotics: Increased risk of seizures.<br />- Anti-platelet agents: Increased risk of gastrointestinal bleeding.<br />- Other NSAIDs: Increased risk of gastrointestinal bleeding.<br />- Methotrexate: Increased serum concentration of methotrexate. Increased toxicity may result. When concomitant therapy has to be used careful monitoring should be undertaken.<br />- Selective serotonin reuptake inhibitors (SSRIs): Increased risk of gastrointestinal bleeding.<br />- Lithium: NSAIDs inhibit renal clearance of lithium, thus the serum concentration of lithium may increase above toxicity limits. Therefore serum lithium levels require monitoring, especially during initiation, adjustment and withdrawal of treatment.<br />- Cyclosporine: Increased serum concentration of cyclosporine. Nephrotoxicity of cyclosporine may be enhanced via renal prostaglandin mediated effects. During combined treatment renal function should be monitored.<br />- Sulphonylureas (e.g. glibenclamide): Increased risk of hypoglycemia.<br />- Known inducers and inhibitors of CYP2C9 isoenzymes: Lornoxicam (as other NSAIDs depending on the cytochrome P450 2C9 (CYP2C9 isoenzyme)) has interactions with known inducers and inhibitors of CYP2C9 isoenzymes.</p><p>- Tacrolimus: Increase the risk of nephrotoxicity owing to reduced synthesis of prostacyclin in the kidney. During combined treatment renal function should be monitored.<br />Food may decrease the absorption with about 20% and increase Tmax.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="FertilityAndPregnantWarnings">4.6. Fertility, pregnancy and lactation</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><strong>Pregnancy</strong><br />Lornoxicam is contraindicated on the third trimester of pregnancy and should not be used during pregnancy in the first and second trimesters and delivery, as no clinical data on exposed pregnancies are available.<br />There are no adequate data from the use of lornoxicam in pregnant women. Studies in animals have shown reproductive toxicity.<br />Inhibition of prostaglandin synthesis may adversely affect the pregnancy and/or the embryo/fetal development. Data from epidemiological studies suggest an increased risk of miscarriage and of cardiac malformation after use of a prostaglandin synthesis inhibitor in early pregnancy. The risk is believed to increase with dose and duration of therapy. In animals, administration of a prostaglandin synthesis inhibitor has been shown to result in increased pre- and post-implantation loss and embryo-foetal lethality. During the first and second trimester of pregnancy, prostaglandin synthesis inhibitors should not be given unless clearly necessary.<br />Prostaglandin synthesis inhibitors administered during the third trimester of pregnancy may expose the fetus to cardiopulmonary toxicity (premature closure of the ductus arteriosus and pulmonary hypertension) and renal dysfunction which may lead to renal failure and hence a reduced quantity of amniotic fluid. At the end of pregnancy, prostaglandin synthesis inhibitors may expose the mother and the fetus to increased bleeding time and inhibition of uterine contractions, which may delay or prolong the labor. Therefore, the use of lornoxicam is contraindicated during the third trimester of pregnancy.</p><p><strong>Breastfeeding</strong><br />There are no data on the excretion of lornoxicam in human breast milk. Lornoxicam is excreted in milk of lactating rats in relatively high concentrations. Therefore lornoxicam should not be used in breastfeeding women.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="EffectsAbilityDriveMachines">4.7. Effects on ability to drive and use machines</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Patients showing dizziness and/or sleepiness under treatment with lornoxicam should refrain from driving or operation machinery.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="UndesirableEffects">4.8. Undesirable effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>The most commonly observed adverse events of NSAIDs are gastrointestinal in nature. Peptic ulcers, perforation or GI bleeding, sometimes fatal, particularly in the elderly, may occur. Nausea, vomiting, diarrhea, flatulence, constipation, dyspepsia, abdominal pain, melena, hematemesis, ulcerative stomatitis, exacerbation of colitis and Crohn&#39;s disease have been reported following administration of NSAIDs. Less frequently, gastritis has been observed.</p><p>Approximately 20% of patients treated with lornoxicam can be expected to experience adverse reactions. The most frequent adverse effects of lornoxicam include nausea, dyspepsia, indigestion, abdominal pain, vomiting, and diarrhea. Edema, hypertension, and cardiac failure, have been reported in association with NSAID treatment.<br />Clinical and epidemiological data suggest that use of some NSAIDs (particularly at high doses and in long term treatment) may be associated with an increased risk of arterial thrombotic events (for example myocardial infarction or stroke).<br />Listed below are undesirable effects: Very common (&ge;1/10); Common (&ge;1/100 to &lt;1/10); Uncommon (&ge;1/1,000 to &lt;1/100); rare (&ge;1/10,000 to &lt;1/1,000); Very rare (&lt;1/10,000), not known (cannot be estimated from the available data).</p><p>Infections and infestations<br />Rare: Pharyngitis.</p><p>Blood and lymphatic system disorders<br />Rare: Anemia, thrombocytopenia, leucopoenia, prolonged bleeding time.<br />Very rare: Ecchymosis.</p><p>Immune system disorders<br />Rare: Hypersensitivity, anaphylactic reaction and anaphylaxis.</p><p>Metabolism and nutrition disorders<br />Uncommon: Anorexia, weight changes.</p><p>Psychiatric disorders<br />Uncommon: Insomnia, depression.<br />Rare: Confusion, nervousness, agitation.</p><p>Nervous system disorders<br />Common: Mild and transient headache, dizziness.<br />Rare: Somnolence, paresthesia, dysgeusia, tremor, migraine.</p><p>Eye disorders<br />Uncommon: Conjunctivitis<br />Rare: Visual disturbances.</p><p>Ear and labyrinth disorders<br />Uncommon: Vertigo, tinnitus.</p><p>Cardiac disorders<br />Uncommon: Palpitations, tachycardia, edema, cardiac failure.</p><p>Vascular disorders<br />Uncommon: Flushing, edema.<br />Rare: Hypertension, hot flush, hemorrhage, hematoma.</p><p>Respiratory, thoracic and mediastinal disorders<br />Uncommon: Rhinitis.<br />Rare: Dyspnea, cough, bronchospasm.</p><p>Gastrointestinal disorders<br />Common: Nausea, abdominal pain, dyspepsia, diarrhea, vomiting.</p><p>Uncommon: Constipation, flatulence, eructation, dry mouth, gastritis, gastric ulcer, abdominal pain upper, duodenal ulcer, mouth ulceration.<br />Rare: Melaena, hematemesis, stomatitis, esophagitis, gastroesophageal reflux, dysphagia, aphthous, stomatitis, glossitis, perforated peptic ulcer.</p><p>Hepatobiliary disorders<br />Uncommon: Increase in liver function tests, SGPT (ALT) or SGOT (AST).<br />Rare: Hepatic function abnormal.<br />Very rare: Hepatocellular damage.</p><p>Skin and subcutaneous tissue disorders<br />Uncommon: Rash, pruritus, hyperhidrosis, rash erythematous, urticaria, alopecia.<br />Rare: Dermatitis and purpura.<br />Very rare: Edema and bullous reactions, Stevens-Johnson syndrome, toxic epidermal necrolysis.</p><p>Musculoskeletal and connective tissue disorders<br />Uncommon: Arthralgia.<br />Rare: Bone pain, muscle spasms, myalgia.</p><p>Renal and urinary disorders<br />Rare: Nocturia, micturition disorders, increase in blood urea nitrogen and creatinine levels.</p><p>General disorders and administration site conditions<br />Uncommon: Malaise, face edema.<br />Rare: Asthenia.</p><p><br />To report any side effect(s):<br />&bull; Saudi Arabia:<br />- National Pharmacovigilance &amp; Drug Safety Centre (NPC):<br />&bull; Fax: +966-11-205-7662<br />&bull; Call NPC at +966-11-2038222, Ext.: 2317-2356-2353-2354-2334-2340.<br />&bull; Toll free phone : 8002490000<br />&bull; E-mail: npc.drug@sfda.gov.sa<br />&bull; Website: www.sfda.gov.sa/npc<br />- Other GCC States:<br />Please contact the relevant competent authority.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Overdoes">4.9. Overdoes</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>At this time, there is no experience of overdose to permit definition of the consequence of an overdose, or to suggest specific managements. However, it can be expected that after an overdose with lornoxicam, the following symptoms can be seen: Nausea, vomiting, cerebral symptoms (dizziness, disturbances in vision). Severe symptoms are ataxia ascending to coma and cramps, liver and kidney damages and maybe coagulation disorders.<br />In the case of a real or suspected overdose, the medicinal product should be withdrawn. Due to its short half-life, lornoxicam is rapidly excreted. Lornoxicam is not dialyzable. No specific antidote is known to date. The usual emergency measures including gastric lavage should be considered.</p><p>Based on principles, only administering activated charcoal immediately after the intake of lornoxicam can lead to diminished absorption of the preparation. Gastrointestinal disorders can for example be treated with a prostaglandin analogue or ranitidine.</p>
            </div>
        </div>
    </div>

    <div class="col-xs-12">
        <label style="float: left">5. PHARMACOLOGICAL PROPERTIES</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PharmacodynamicProperties">5.1. Pharmacodynamic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><strong>Pharmacotherapeutic group: </strong>anti-inflammatory and anti-rheumatic products, non-steroids, oxicams<br /><strong>ATC code: </strong>M01 AC05<br /><strong>Mechanism of action</strong><br />Lornoxicam is a non-steroidal anti-inflammatory drug with analgesic properties and belongs to the class of oxicams. Lornoxicams mode of action is mainly related to the inhibition of the prostaglandin synthesis (inhibition of the cyclooxygenase enzyme) leading to desensitization of peripheral nociceptors and consequently inhibition of inflammation. A central effect on nociception, which seems to be independent of anti-inflammatory effects has also been suggested.</p><p><br /><u>Pharmacodynamic effects</u><br />Lornoxicam has no effect on vital signs (e.g. body temperature, respiratory rate, heart rate, blood pressure, ECG, spirometry).<br /><u>Clinical efficacy and safety</u><br />The analgesic properties of lornoxicam have been demonstrated successfully in several clinical trials during development of the drug.<br />Due to a local gastrointestinal irritation and a systemic ulcerogenic effect related to the inhibition of prostaglandin (PG)-synthesis, gastrointestinal sequelae are common undesirable effects after treatment with lornoxicam as seen with other NSAIDs.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
                <label style="float: left" for="PharmacokineticProperties">5.2. Pharmacokinetic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Absorption<br />Lornoxicam is absorbed rapidly and almost completely from the gastrointestinal tract. Maximum plasma concentrations are achieved after approximately 1-2 hours. The absolute bioavailability of lornoxicam is 90-100%. No first-pass effect has been observed. The mean elimination half-life is 3-4 hours.<br />Simultaneous intake of lornoxicam with meals reduces Cmax by approximately 30% and Tmax increases from 1.5 to 2.3 hours. The absorption of lornoxicam (calculated on AUC) can be reduced up to 20%.</p><p><br />Distribution<br />Lornoxicam is found in the plasma in unchanged form and as its hydroxylated metabolite. The plasma protein binding of lornoxicam is 99% and not concentration dependent.</p><p><br />Biotransformation<br />Lornoxicam is extensively metabolized in the liver, primarily to the inactive 5&ndash;hydroxylornoxicam by hydroxylation. CYP2C9 is involved in this biotransformation of lornoxicam. Due to genetic polymorphism, slow and extensive metabolizers exist for this enzyme, which could result in markedly, increased plasma levels of lornoxicam in slow metabolizers. The hydroxylated metabolite exhibits no pharmacological activity. Lornoxicam is metabolized completely, and approximately 2/3 is eliminated via the liver and 1/3 via the kidneys as inactive substance.</p><p>When tested in animal models, lornoxicam did not induce liver enzymes. From clinical data there is no evidence of accumulation of lornoxicam after repeated administrations, when given according to recommended dosage. This finding was supported by drug monitoring data.</p><p><br />Elimination<br />The mean elimination half-life of the parent compound is 3 to 4 hours. After oral administration about 50% is excreted in the feces and 42% through the kidneys, mainly as 5-hydroxylornoxicam. The elimination half-life of 5-hydroxylornoxicam is about 9 hours after a parenteral single or twice daily dose.<br />In elderly patients above age 65, the clearance is reduced with 30-40%. Apart from reduced clearance, there is no significant change in the kinetic profile of lornoxicam in elderly patients.<br />There is no significant change in the kinetic profile of lornoxicam in patients with renal or hepatic failure, except for accumulation in patients with chronic liver disease after 7 days of treatment with daily doses of 12 and 16 mg.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PreclinicalSafetyData">5.3 Preclinical Safety Data</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Non-clinical data reveal no special hazard for humans based on conventional studies of safety pharmacology, repeated dose toxicity, genotoxicity, and carcinogenic potential.<br />Lornoxicam caused renal toxicity and gastrointestinal ulceration single- and repeat-dose toxicity studies in several species.<br />In animals, administration of prostaglandin synthesis inhibitor has been shown to result in increased pre- and post-implantation loss and embryo-fetal lethality. In addition, increased incidences of various malformations, including cardiovascular, have been reported in animals given a prostaglandin synthesis inhibitor during the organogenetic period.<br />In rat, lornoxicam impaired fertility (effects on ovulation and implantation), and affected the pregnancy and delivery. In rabbit and rat, lornoxicam caused premature closure of the ductus arteriosus due to inhibition of cyclooxygenase.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. PHARMACEUTICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ExcipientsList">6.1 Excipients List</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Lactose regular,<br />Microcrystalline Cellulose,<br />Povidone K30,<br />Crosscarmellose Sodium,<br />Magnesium Stearate &amp;<br />Opadry White.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Incompatibilities">6.2. Incompatibilities</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Not applicable.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ShelfLife">6.3. Shelf Life</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                2 years.
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PrecautionsStorageConditions">6.4. Special precautions for storage</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Do not store above 30&deg;C.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ContainerContents">6.5. Nature and contents of container</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>LEROXO&reg; F.C. Tablets are packed in Aluminum foil, PVC/ PVC blisters, with a multi folded leaflet packed in registration box.<br />Pack size: 10 &amp; 20 F.C. Tablets</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialPrecautionsDisposal">6.6. Special precautions for disposal and other handling</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Any unused product or waste should be disposed of in accordance with local requirements.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="AuthorizationMarketingHolder">7. MARKETING AUTHORISATION HOLDER</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                The United Pharmaceutical Mfg. Co. Ltd.
P.O. Box 69, Amman 11591-Jordan
Tel: + 962 (6) 416 2901
Fax: + 962 (6) 416 2905
E-mail: upm_info@mspharma.com
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="RevisionDateText">8. DATE OF REVISION OF THE TEXT</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Nov., 2017
            </div>
        </div>
    </div>
</div>

            }    </div>
    <div id="f-div" class="box-data">
        
<div class="row clearfix rtl">
    <div class="container-fluid">
        <!-- Basic Example -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>صورة المنتج على الرف</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic" data-slide-to="0" class="active"></li>
                        <li data-target="#carousel-example-generic" data-slide-to="1" class=""></li>
                        <li data-target="#carousel-example-generic" data-slide-to="2" class=""></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                            
                                <img src="/images/nodrugimags.png">
                        </div>

                    </div>

                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# Basic Example -->
        <!-- With Captions -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>الصورة الاساسية</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic_2" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic_2" data-slide-to="0" class=""></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="1" class="active"></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="2"></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                                <img src="/images/nodrugimags.png">
                        </div>
                    </div>
                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic_2" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic_2" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# With Captions -->
    </div>
</div>


    </div>

    <!-- #END# Tabs With Custom Animations -->
</div>
        <a style="background-image: url('../images/banner.png');"
           class="scroll-top">
            <img style="margin: 15px;" src="/images/icons/up-arrow2.png" width="35">
        </a>

        <div class="footer navbar-fixed-bottom">
            <small style="color: white; margin-left: 30px;">All Rights Reserved - SFDA &copy; 2020</small>
            <br class="visible-xs visible-sm"><br class="visible-xs visible-sm">

        </div>
    </section>


    <script src="/lib/json2/json2.js?v=w3DjWhUtDqy3bSJKv285C-2kagUtW9F64T9z3xRah8g"></script>
    <script src="/lib/jquery/dist/jquery.js?v=w4hyv6-vmv08RC2hK00wXgxDziKII9paMAbU_M-5dgY"></script>
    <script src="/lib/bootstrap/dist/js/bootstrap.js?v=T574NvJTWc-Pan8hAmnXXc0eZFiqKRp7xQ3sz5QiFOk"></script>
    <script src="/lib/moment/min/moment-with-locales.js?v=5f0RFtuChrGi6osDzegxXWf5yOkmx45i7J9fM1p6P5w"></script>
    <script src="/lib/jquery-validation/dist/jquery.validate.js?v=ZDzsHzuLAtqQVxXwbgRtfAPXQ7UAoJRXBAUDvc9G9CI"></script>
    <script src="/lib/blockUI/jquery.blockUI.js?v=KKcUNqwNyTLaXzvuMyFk6JisiQq6Hk7ZtrciXnEf3Z0"></script>
    <script src="/lib/toastr/toastr.js?v=s1ewxfN8Vn23TAVRLUk8XiQUAw6uWhhuPO9dmtYzUiA"></script>
    <script src="/lib/sweetalert/dist/sweetalert.min.js?v=aPktydUv1rN3mouQeXoKi3ioFTIQlULuqYeoTAA2ihY"></script>
    <script src="/lib/spin.js/spin.js?v=b1plKpQIB-XuGyjWec42MhmhpPzEPzFI3OC8Ia0XIoc"></script>
    <script src="/lib/spin.js/jquery.spin.js?v=i7H7HL08ldqUANgfQInE7LlU2uWUdQMCJ-Q7-_zLutY"></script>
    <script src="/lib/bootstrap-select/dist/js/bootstrap-select.js?v=tXulJKckrq2j2wo8a9hvmXLDEQwhGviPTIYmEzy1dNI"></script>
    <script src="/lib/jquery-slimscroll/jquery.slimscroll.js?v=ESVSX4dkOxamaRoYfcqPM2FfErhgfxS60fp1Fa8ou1w"></script>
    <script src="/lib/Waves/dist/waves.js?v=ZOMv1vwqpT_ezNZGhvr9jJTr_jqu3lYHB7vmpxD7HmA"></script>
    <script src="/lib/push.js/push.js?v=w347yqiscLjM_TxUKpqeUA1LDR3w5vshQpxpTsgkLhE"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/abp.js?v=EjNSmvtPSqCVK_xG_aTvOp8hmVM_7vwyd3hg45CAMGk"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.jquery.js?v=XEXcdRYb4eN3XoQCbnM-BSR6UifHRLsXYDIVFZ7Oc6Q"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.toastr.js?v=h3viOCmHM1K7HnYUuJPDvLchk2Ge8CoKvl6ZJfICgII"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.blockUI.js?v=vMuHbqHh635SKL2RG2qsGGCDyHg1yFeGqhPKpS34g4k"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.spin.js?v=djoKib6ssm5DDzbXLe5pD7ayfFg3siaoEk-BFYzQlvI"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.sweet-alert.js?v=fPp3O_ILaqD0UHiR721w1i4iBtxo3NH7yfldI5dg0_I"></script>
    <script src="/js/admin.js?v=nakObLuf3yPs2VlWrIris5w-48c36X3YIRrxIis7IKQ"></script>
    <script src="/js/main.js?v=x_HDlXByl0okIi4i04d4Q_fNr85GPQi1W8gjs82s-n8"></script>
    <script src="/view-resources/Views/Shared/_Layout.js?v=36YkLzPJaGejZMB10f2T6f1rMVIzDKq96kjfcnxcLVg"></script>


        <script src="/lib/jquery-validation/src/localization/messages_ar.js?v=6kzy-p-PtvkHPWdHWyjMOIfwhBFlUYYv9jnF7zJnpUI"></script>

    <!-- Dynamic scripts of ABP system (They are created on runtime and can not be bundled) -->
    <script src="/AbpServiceProxies/GetAll?v=638865394571695575" type="text/javascript"></script>
    <script src="/AbpScripts/GetScripts?v=638865394571695575" type="text/javascript"></script>
    <script src="/lib/signalr-client/signalr.min.js?v=1yGr-J4NjYMQVt6LP6vocjHIWhO-BFQLfdCs8x1Mv-U"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.signalr-client.js?v=jTdZBAadu6DXq0iDTFX6vsn4q6bFhKm3XfN8Jz6dSmg"></script>
    
    <!-- View specific scripts -->
    
    <script src="/view-resources/Views/Home/Index.js?v=mAIakROmG_IlahImCtfrMSdaLPTG5Uoh6Z0hM1g3cxw"></script>
    <script src="/view-resources/Views/Home/Result.js?v=0pEgOuTQc8ZyJaaOpJCG7ytkKSCkzEMYCHEJfKDWu4k"></script>
    <script src="/view-resources/Views/Home/DrugsSearch.js?v=04aRniTG_ClH5tABzf7EDwQgWVpkDNpjeJUDSGvOK_Y"></script>

</body>
</html>